Mice mutant for genes associated with schizophrenia: Common phenotype or distinct endophenotypes?

Behavioural Brain Research

Volumn 204, Issue 2, 2009, Pages 258-273

  Desbonnet, Lieve ^a   Waddington, John L ^a   O'Tuathaigh, Colm M P ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

Endophenotype; Gene environment interaction; Mutant models; Pathophysiology; Phenotype; Schizophrenia; Susceptibility genes

Indexed keywords

AMINO ACID OXIDASE; BETA SECRETASE; BINDING PROTEIN; CLOZAPINE; COMPLEXIN 1; DISRUPTED IN SCHIZOPHRENIA 1 PROTEIN; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DYSBINDIN; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FLUPENTIXOL; GENE PRODUCT; GLUTAMATE TRANSPORTER; GLYCINE; HALOPERIDOL; LYSOPHOSPHATIDIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEU DIFFERENTIATION FACTOR; NEUROLEPTIC AGENT; NUCLEAR RECEPTOR RELATED FACTOR 1; PHENCYCLIDINE; POLYPEPTIDE; PROTEIN SYNGAP; REELIN; RISPERIDONE; SERINE; SYNAPSIN II; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ARTICLE; BEHAVIOR DISORDER; BRAIN DISEASE; COGNITIVE DEFECT; DEVELOPMENTAL DISORDER; DISEASE COURSE; DRUG RESPONSE; ENVIRONMENTAL FACTOR; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; LEARNING DISORDER; LIFE EVENT; MEMORY DISORDER; NEUROBIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RISK ASSESSMENT; SCHIZOPHRENIA; SOCIAL BEHAVIOR; SOCIAL INTERACTION; SOCIOPATHY; SYMPTOM;

ANIMALS; DISEASE MODELS, ANIMAL; ENVIRONMENT; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; MICE; MICE, TRANSGENIC; PHENOTYPE; SCHIZOPHRENIA;

EID: 69249221567     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.04.001     Document Type: Article

References (184)

1. Allen N.C., Bagade S., McQueen M.B., Ioannidis J.P., Kavvoura F.K., Khoury M.J., et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Genet 40 (2008) 827-834
2. Almond S.L., Fradley R.L., Armstrong E.J., Heavens R.B., Rutter A.R., Newman R.J., et al. Behavioral and biochemical characterization of a mutant mouse train lacking d-amino acid oxidase activity and its implications for schizophrenia. Mol Cell Neurosci 32 (2006) 324-334
3. Andrieux A., Salin P.A., Vernet M., Kujala P., Baratier J., Gory-Faure S., et al. The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioural disorders. Genes Dev 16 (2002) 2350-2364
4. Arguello P.A., and Gogos J.A. Modeling madness in mice: one piece at a time. Neuron 52 (2006) 179-196
5. Babovic D., O'Tuathaigh C.M., O'Connor A.M., O'Sullivan G.J., Tighe O., Croke D.T., et al. Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase. Neuroscience 155 (2008) 1021-1029
6. Babovic D., O'Tuathaigh C.M., O'Sullivan G.J., Clifford J.J., Tighe O., Croke D.T., et al. Exploratory and habituation phenotype of heterozygous and homozygous COMT knockout mice. Behav Brain Res 183 (2007) 236-239
7. Ballard T.M., Pauly-Evers M., Higgins G.A., Ouagazzal A.M., Mutel V., Borroni E., et al. Severe impairment of NMDA receptor function in mice carrying targeted point mutations in the glycine binding site results in drug-resistant nonhabituating hyperactivity. J Neurosci 22 (2002) 6713-6723
8. Basu AC, Tsai GE, Ma CL, Ehmsen JT, Mustafa AK, Han L, et al. Targeted disruption of serine racemase affects glutamatergic neurotransmission and behaviour. Mol Psychiatry 2008 [in press].
9. Begou M., Brun P., Bertrand J.B., Job D., Schweitzer A., D'Amato T., et al. Post-pubertal emergence of alterations in locomotor activity in stop null mice. Synapse 61 (2007) 689-697
10. Bendikov I., Nadri C., Amar S., Panizzutti R., De Miranda J., Wolosker H., et al. A CSF and postmortem brain study of d-serine metabolic parameters in schizophrenia. Schizophr Res 90 (2007) 41-51
11. Bersudsky Y., Shaldubina A., Kozlovsky N., Woodgett J.R., Agam G., and Belmaker R.H. Glycogen synthase kinase-3beta heterozygote knockout mice as a model of findings in postmortem schizophrenia brain or as a model of behaviors mimicking lithium action: negative results. Behav Pharmacol 19 (2008) 217-224
12. Boucher A.A., Arnold J.C., Duffy L., Schofield P.R., Micheau J., and Karl T. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology 192 (2007) 325-336
13. Boucher A.A., Hunt G.E., Karl T., Micheau J., McGregor I.S., and Arnold J.C. Heterozygous neuregulin 1 mice display greater baseline and Delta(9)-tetrahydrocannabinol-induced c-Fos expression. Neuroscience 149 (2007) 861-870
14. Bouvrais-Veret C., Weiss S., Andrieux A., Schweitzer A., McIntosh J.M., Job D., et al. Sustained increase of alpha7 nicotinic receptors and choline-induced improvement of learning deficit in STOP knock-out mice. Neuropharmacology 52 (2007) 1691-1700
15. Braff D.L., Freedman R., Schork N.J., and Gottesman I.I. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr Bull 33 (2007) 21-32
16. Brenner E., Sonnewald U., Schweitzer A., Andrieux A., and Nehlig A. Hypoglutamatergic activity in the STOP knockout mouse: a potential model for chronic untreated schizophrenia. J Neurosci Res 85 (2007) 3487-3493
17. Brigman J.L., Padukiewicz K.E., Sutherland M.L., and Rothblat L.A. Executive functions in the heterozygous reeler mouse model of schizophrenia. Behav Neurosci 120 (2006) 984-988
18. Brun P., Begou M., Andrieux A., Mouly-Badina L., Clerget M., Schweitzer A., et al. Dopaminergic transmission in STOP null mice. J Neurochem 94 (2005) 63-73
19. Burmistrova O.A., Goltsov A.Y., Abramova L.I., Kaleda V.G., Orlova V.A., and Rogaev E.I. MicroRNA in schizophrenia: genetic and expression analysis of miR-130b (22q11). Biochemistry (Moscow) 72 (2007) 578-582
20. Burnet P.W., Hutchinson L., von Hesling M., Gilbert E.J., Brandon N.J., Rutter A.R., et al. Expression of d-serine and glycine transporters in the prefrontal cortex and cerebellum in schizophrenia. Schizophr Res 102 (2008) 283-294
21. van den Buuse M., Martin S., Brosda J., Leck K.J., Matthaei K.I., and Hendry I. Enhanced effect of dopaminergic stimulation on prepulse inhibition in mice deficient in the alpha subunit of G(z). Psychopharmacology 183 (2005) 358-367
22. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene × environment interaction. Biol Psychiatry 57 (2005) 1117-1127
23. Castner S.A., and Williams G.V. Tuning the engine of cognition: a focus on NMDA/D1 receptor interactions in prefrontal cortex. Brain Cogn 63 (2007) 94-122
24. Chen J., Lipska B.K., and Weinberger D.R. Genetic mouse models of schizophrenia: from hypothesis-based to susceptibility gene-based models. Biol Psychiatry 59 (2006) 1180-1188
25. Chen Y.J., Johnson M.A., Lieberman M.D., Goodchild R.E., Schobel S., Lewandowski N., et al. Type III neuregulin-1 is required for normal sensorimotor gating, memory-related behaviors, and corticostriatal circuit components. J Neurosci 28 (2008) 6872-6883
26. Chowdari K.V., Mirnics K., Semwal P., Wood J., Lawrence E., Bhatia T., et al. Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum Mol Genet 11 (2002) 1373-1380
27. Chubb J.E., Bradshaw N.J., Soares D.C., Porteous D.J., and Millar J.K. The DISC locus in psychiatric illness. Mol Psychiatry 13 (2008) 36-64
28. Chumakov I., Blumenfeld M., Guerassimenko O., Caverec L., Palicio M., Abderrahim H., et al. Genetic and physiological data implicating the new human gene G72 and the gene for d-amino acid oxidase in schizophrenia. Proc Natl Acad Sci USA 99 (2002) 13675-13680
29. Clapcote S.J., Lipina T.V., Millar J.K., Mackie S., Christie S., Ogawa F., et al. Behavioral phenotypes of Disc1 missense mutations in mice. Neuron 54 (2007) 387-402
30. Clapcote S.J., and Roder J.C. Deletion polymorphism of Disc1 is common to all 129 mouse substrains: implications for gene-targeting studies of brain function. Genetics 173 (2006) 2407-2410
31. Corfas G., Roy K., and Buxbaum J.D. Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nat Neurosci 7 (2004) 575-580
32. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol 26 (2006) 365-384
33. Crabbe J.C., and Morris R.G. Festina lente: late-night thoughts on high-throughput screening of mouse behaviour. Nat Neurosci 23 (2004) 1175-1179
34. Craddock N., O'Donovan M.C., and Owen M.J. Genes for schizophrenia and bipolar disorder? Implications for psychiatric nosology. Schizophr Bull 32 (2006) 9-16
35. Cryan J.F., Thakker D.R., and Hoyer D. Emerging use of non-viral RNA interference in the brain. Biochem Soc Trans 35 (2007) 411-415
36. Dominguez D., Tournoy J., Hartmann D., Huth T., Cryns K., Deforce S., et al. Phenotypic and biochemical analyses of BACE1- and BACE2-deficient mice. J Biol Chem 280 (2005) 30797-30806
37. Dowal L., Elliott J., Popov S., Wilkie T.M., and Scarlata S. Determination of the contact energies between a regulator of G protein signaling and G protein subunits and phospholipase C beta 1. Biochemistry 40 (2001) 414-421
38. Drew C.J., Kyd R.J., and Morton A.J. Complexin 1 knockout mice exhibit marked deficits in social behaviours but appear to be cognitively normal. Hum Mol Genet 16 (2007) 2288-2305
39. Duan X., Chang J.H., Ge S., Faulkner R.L., Kim J.Y., Kitabatake Y., et al. Disrupted-in-schizophrenia 1 regulates integration of newly generated neurons in the adult brain. Cell 130 (2007) 1146-1158
40. Duncan G.E., Moy S.S., Lieberman J.A., and Koller B.H. Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function. Psychopharmacology 184 (2006) 190-200
41. Duncan G.E., Moy S.S., Perez A., Eddy D.M., Zinzow W.M., Lieberman J.A., et al. Deficits in senosrimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. Behav Brain Res 153 (2004) 507-519
42. Dyck B.A., Skoblenick K.J., Castellano K.M., Ki K., Thomas N., and Mishra R.K. Synapsin II knockout mice show sensorimotor gating and behavioural abnormalities similar to those in the phencyclidine-induced preclinical animal model of schizophrenia. Schizophr Res 97 (2007) 292-293
43. Eastwood S.L., Lyon L., George L., Andrieux A., Job D., and Harrison P.J. Altered expression of synaptic protein mRNAs in STOP (MAP6) mutant mice. J Psychopharmacol 21 (2007) 635-644
44. Eells J.B., Misler J.A., and Nikodem V.M. Early postnatal isolation reduces dopamine levels, elevates dopamine turnover and specifically disrupts prepulse inhibition in Nurr1-null heterozygous mice. Neuroscience 140 (2006) 1117-1126
45. Egan M.F., Goldberg T.E., Kolachana B.S., Callicott J.H., Mazzanti C.M., Straub R.E., et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 98 (2001) 6917-6922
46. Ellenbroek B.A., and Cools A.R. Animal models for the negative symptoms of schizophrenia. Behav Pharmacol 11 (2000) 223-233
47. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., and Gogos J.A. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 36 (2004) 131-137
48. Enomoto T., Noda Y., and Nabeshima T. Phencyclidine and genetic animal models of schizophrenia developed in relation to the glutamate hypothesis. Methods Find Exp Clin Pharmacol 29 (2007) 291-301
49. Feng Y.Q., Zhou Z.Y., He X., Wang H., Guo X.L., Hao C.J., et al. Dysbindin deficiency in sandy mice causes reduction of snapin and displays behaviors related to schizophrenia. Schizophr Res 106 (2008) 218-228
50. Flint J., and Shifman S. Animal models of psychiatric disease. Curr Opin Genet Dev 18 (2008) 235-240
51. Fradley R.L., O'Meara G.F., Newman R.J., Andrieux A., Job D., and Reynolds D.S. STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav Brain Res 163 (2005) 257-264
52. Gerber D.J., Hall D., Miyakawa T., Demars S., Gogos J.A., Karayiorgou M., et al. Evidence for association of schizophrenia with genetic variation in the 8p21.3 gene, PPP3CC, encoding the calcineurin gamma subunit. Proc Natl Acad Sci USA 100 (2003) 8993-8998
53. Gerlai R., Pisacane P., and Erickson S. Heregulin, but not ErbB2 or ErbB3, heterozygous mutant mice exhibit hyperactivity in multiple behavioral tasks. Behav Brain Res 109 (2000) 219-227
54. Geyer M.A. Developing translational animal models for symptoms of schizophrenia or bipolar mania. Neurotox Res 14 (2008) 71-78
55. Gogos J.A., Santha M., Takacs Z., Beck K.D., Luine V., Lucas L.R., et al. The gene encoding proline dehydrogenase modulates sensorimotor gating in mice. Nat Genet 21 (1999) 434-439
56. Gogos J.A. Schizophrenia susceptibility genes: in search of a molecular logic and novel drug targets for a devastating disorder. Int Rev Neurobiol 78 (2007) 397422
57. Gogos J.A., Morgan M., Luine V., Santha M., Ogawa S., Pfaff D., et al. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior. Proc Natl Acad Sci USA 95 (1998) 9991-9996
58. Gogos J.A., and Gerber D.J. Schizophrenia susceptibility genes: emergence of positional candidates and future directions. Trends Pharmacol Sci 27 (2006) 226-233
59. Golub M.S., Germann S.L., and Lloyd K.C. Behav Behavioral characteristics of a nervous system-specific erbB4 knock-out mouse. Brain Res 153 (2004) 159-170
60. Gray L., and Hannan A.J. Dissecting cause and effect in the pathogenesis of psychiatric disorders: genes, environment and behaviour. Curr Mol Med 7 (2007) 470-478
61. Grillet N., Pattyn A., Contet C., Kieffer B.L., Goridis C., and Brunet J.F. Generation and characterization of Rgs4 mutant mice. Mol Cell Biol 10 (2005) 4221-4228
62. Guillin O., Abi-Dargham A., and Laruelle M. Neurobiology of dopamine in schizophrenia. Int Rev Neurobiol 78 (2007) 1-39
63. Guo X, Hamilton PJ, Reish NJ, Sweatt JD, Miller CA, Rumbaugh G. Reduced Expression of the NMDA receptor-interacting protein SynGAP causes behavioral abnormalities that model symptoms of schizophrenia. Neuropsychopharmacology, 2009 [in press].
64. Haasio K., Huotari M., Nissinen E., and Männistö P.T. Tissue histopathology, clinical chemistry and behaviour of adult Comt-gene-disrupted mice. J Appl Toxicol 23 (2003) 213-219
65. Hahn C.G., Wang H.Y., Cho D.S., Talbot K., Gur R.E., Berrettini W.H., et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med 12 (2006) 824-828
66. Hains A.B., and Arnsten A.F. Molecular mechanisms of stress-induced prefrontal cortical impairment: implications for mental illness. Learn Mem 15 (2008) 551-564
67. Hansen T., Olsen L., Lindow M., Jakobsen K.D., Ullum H., Jonsson E., et al. Brain expressed microRNAs implicated in schizophrenia etiology. PLoS ONE 2 (2007) e873
68. Haroutunian V., and Davis K.L. Introduction to the special section: myelin and oligodendrocyte abnormalities in schizophrenia. Int J Neuropsychopharmacol 10 (2007) 499-502
69. Harrison P.J., and Law A.J. Neuregulin 1 and schizophrenia: genetics, gene expression, and neurobiology. Biol Psychiatry 60 (2006) 132-140
70. Harrison P.J., and Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10 (2005) 40-68
71. Harrison S.M., Reavill C., Brown G., Brown J.T., Cluderay J.E., Crook B., et al. LPA1 receptor-deficient mice have phenotypic changes obseved in psychiatric disease. Mol Cell Neurosci 24 (2003) 1170-1179
72. Hashimoto A., Yoshikawa M., Niwa A., and Konno R. Mice lacking d-amino acid oxidase activity display marked attenuation of stereotypy and ataxia induced by MK-801. Brain Res 1033 (2005) 210-215
73. Hashimoto A., Nishikawa T., Konno R., Niwa A., Yasumura Y., Oka T., et al. Free d-serine, d-aspartate and d-alanine in central nervous system and serum in mutant mice lacking d-amino acid oxidase. Neurosci Lett 152 (1993) 33-36
74. Hashimoto A., Konno R., Yano H., Yoshikawa M., Tamaki R., Matsumoto H., et al. Mice lacking d-amino acid oxidase activity marked reduction of methamphetamine-induced stereotypy. Eur J Pharmacol 586 (2008) 221-225
75. Hashimoto K., Fukushima T., Shimizu E., Komatsu N., Watanabe H., Shinoda N., et al. Decreased serum levels of d-serine in patients with schizophrenia: evidence in support of the N-methyl-d-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 60 (2003) 572-576
76. Hattori S., Murotani T., Matsuzaki S., Ishizuka T., Kumamoto N., Takeda M., et al. Behavioral abnormalities and dopamine reductions in sdy mutant mice with a deletion in Dtnbp1, a susceptibility gene for schizophrenia. Biochem Biophys Res Commun 373 (2008) 298-302
77. Hennah W., Tuulio-Henriksson A., Paunio T., Ekelund J., Varilo T., Partonen T., et al. A haplotype within the DISC1 gene is associated with visual memory functions in families with a high density of schizophrenia. Mol Psychiatry 10 (2005) 1097-1103
78. Hennessy R.J., Kinsella A., Baldwin P., and Waddington J.L. 3D laser surface imaging and geometric morphometrics resolve frontonasal dysmorphology in schizophrenia. Biol Psychiatry 61 (2007) 1187-1194
79. Heresco-Levy U., Javitt D.C., Ebstein R., Vass A., Lichtenberg P., Bar G., et al. d-Serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia. Biol Psychiatry 57 (2005) 577-585
80. Hikida T., Jaaro-Peled H., Seshadri S., Oishi K., Hookway C., Kong S., et al. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc Natl Acad Sci USA 104 (2007) 14501-14506
81. Holmans PA, Riley B, Pulver AE, Owen MJ, Wildenauer DB, Gejman PV, et al. Genomewide linkage scan of schizophrenia in a large multicenter pedigree sample using single nucleotide polymorphisms. Mol Psychiatry [in press].
82. Hsu R., Woodroffe A., Lai W.S., Cook M.N., Mukai J., Dunning J.P., et al. Nogo Receptor 1 (RTN4R) as a candidate gene for schizophrenia: analysis using human and mouse genetic approaches. PLoS ONE 2 (2007) e1234
83. Huotari M., Santha M., Lucas L.R., Karayiorgou M., Gogos J.A., and Männistö P.T. Effect of dopamine uptake inhibition on brain catecholamine levels and locomotion in catechol-O-methyltransferase-disrupted mice. J Pharmacol Exp Ther 303 (2002) 1309-1316
84. Huotari M., García-Horsman J.A., Karayiorgou M., Gogos J.A., and Männistö P.T. d-Amphetamine responses in catechol-O-methyltransferase (COMT) disrupted mice. Psychopharmacology 172 (2004) 1-10
85. Hu X., Hicks C.W., He W., Wong P., Macklin W.B., Trapp B.D., et al. Bace1 modulates myelination in the central and peripheral nervous system. Nat Neurosci 9 (2006) 1520-1525
86. International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature, 2008; 455: 237-41.
87. Kalueff A.V., Wheaton M., and Murphy D.L. What's wrong with my mouse model? Advances and strategies in animal modeling of anxiety and depression. Behav Brain Res 179 (2007) 1-18
88. Kamiya A., Kubo K., Tomoda T., Takaki M., Youn R., Ozeki Y., et al. A schizophrenia-associated mutation of DISC1 perturbs cerebral cortex development. Nat Cell Biol 7 (2005) 1167-1178
89. Kapur S., Mizrahi R., and Li M. From dopamine to salience to psychosis-linking biology, pharmacology and phenomenology of psychosis. Schizophr Res 79 (2005) 59-68
90. Karayiorgou M., and Gogos J.A. Schizophrenia genetics: uncovering positional candidate genes. Eur J Hum Genet 14 (2006) 512-519
91. Karl T., Duffy L., Scimone A., Harvey R.P., and Schofield P.R. Altered motor activity, exploration and anxiety in heterozygous neuregulin 1 mutant mice: implications for understanding schizophrenia. Genes Brain Behav 6 (2007) 677-687
92. Karlsson R.M., Tanaka K., Heilig M., and Holmes A. Loss of glial glutamate and aspartate transporter (excitatory amino acid transporter 1) causes locomotor hyperactivity and exaggerated responses to psychotomimetics: rescue by haloperidol and metabotropic glutamate 2/3 agonist. Biol Psychiatry 64 (2008) 810-814
93. Karlsson R.M., Tanaka K., Saksida L.M., Bussey T.J., Heilig M., and Holmes A. Assessment of glutamate transporter GLAST (EAAT1)-deficient mice for phenotypes relevant to the negative and executive/cognitive symptoms of schizophrenia. Neuropsychopharmacology 34 (2009) 1578-1589
94. Karoutzou G., Emrich H.M., and Dietrich D.E. The myelin-pathogenesis puzzle in schizophrenia: a literature review. Mol Psychiatry 13 (2008) 245-260
95. Kas M.J., and Van Ree J.M. Dissecting complex behaviours in the post-genomic era. Trends Neurosci 27 (2004) 366-369
96. Kellendonk C., Simpson E.H., Polan H.J., Malleret G., Vronskaya S., Winiger V., et al. Transient and selective overexpression of dopamine D2 receptors in the striatum cause persistent abnormalities in prefrontal cortex functioning. Neuron 49 (2006) 484-485
97. Klejbor I., Myers J.M., Hausknecht K., Corso T.D., Gambino A.S., Morys J., et al. Fibroblast growth factor receptor signalling affects development and function of dopamine neurons-inhibition results in a schizophrenia-like syndrome in transgenic mice. J Neurochem 97 (2006) 1243-1258
98. Kocerha J., Faghihi M.A., Lopez-Toledano M.A., Huang J., Ramsey A.J., Caron M.G., et al. MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction. Proc Natl Acad Sci USA 106 (2009) 3507-3512
99. Koh H.Y., Kim D., Lee J., Lee S., and Shin H.S. Deficits in social behavior and sensorimotor gating in mice lacking phospholipase Cbeta1. Genes Brain Behav 7 (2008) 120-128
100. Koike H., Arguello P.A., Kvajo M., Karayiorgou M., and Gogos J.A. Disc1 is mutated in the 129S6/SvEv strain and modulates working memory in mice. Proc Natl Acad Sci USA 103 (2006) 3693-3697
101. Krivoy A., Fischel T., and Weizman A. The possible involvement of metabotropic glutamate receptors in schizophrenia. Eur Neuropsychopharmacol 18 (2008) 395-405
102. Krueger D.D., Howell J.L., Hebert B.F., Olausson P., Taylor J.R., and Nairn AC. Assessment of cognitive function in the heterozygous reeler mouse. Psychopharmacology 189 (2006) 95-104
103. Kvajo M., McKellar H., Arguello P.A., Drew L.J., Moore H., MacDermott A.B., et al. A mutation in mouse Disc 1 that models a schizophrenia risk allele leads to specific alterations in neuronal architecture and cognition. Proc Natl Acad Sci USA 105 (2008) 7076-7081
104. Labrie V., Lipina T., and Roder J.C. Mice with reduced NMDA receptor glycine affinity model some of the negative and cognitive symptoms of schizophrenia. Psychopharmacology 200 (2008) 217-230
105. Lai W.S., Xu B., Westphal K.G., Paterlini M., Olivier B., Pavlidis P., et al. Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc Natl Acad Sci USA 103 (2006) 16906-16911
106. Lane H.Y., Chang Y.C., Liu Y.C., Chiu C.C., and Tsai G.E. Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Arch Gen Psychiatry 62 (2005) 1196-1204
107. Law A.J., Kleinman J.E., Weinberger D.R., and Weickert C.S. Disease-associated intronic variants in the ErbB4 gene are related to altered ErbB4 splice-variant expression in the brain in schizophrenia. Hum Mol Genet 16 (2007) 129-141
108. Levitt P., Ebert P., Mirnics K., Nimgaonkar V.L., and Lewis D.A. Making the case for a candidate vulnerability gene in schizophrenia: convergent evidence for regulator of G-protein signaling 4 (RGS4). Biol Psychiatry 60 (2006) 534-537
109. Li D., Collier D.A., and He L. Meta-analysis shows strong positive association of the neuregulin 1 (NRG1) gene with schizophrenia. Hum Mol Genet 15 (2006) 1995-2002
110. Li W., Zhang Q., Oiso N., Novak E.K., Gautam R., O'Brien E.P., et al. Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Nat Genet 35 (2003) 84-89
111. Li W., Zhou Y., Jentsch J.D., Brown R.A., Tian X., Ehninger D., et al. Specific developmental disruption of disrupted-in-schizophrenia-1 function results in schizophrenia-related phenotypes in mice. Proc Natl Acad Sci USA 104 (2007) 18280-18285
112. Lipska B.K., and Weinberger D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 23 (2000) 223-239
113. Liu H., Heath S.C., Sobin C., Roos J.L., Galke B.L., Blundell M.L., et al. Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. Proc Natl Acad Sci USA 99 (2002) 3717-3722
114. Liu Y.L., Fann C.S., Liu C.M., Chang C.C., Yang W.C., Wu J.Y., et al. HTF9C gene of 22q11.21 region associates with schizophrenia having deficit-sustained attention. Psychiatr Genet 17 (2007) 333-338
115. Lovestone S., Killick R., Di Forti M., and Murray R. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci 30 (2007) 142-149
116. Maekawa M., Watanabe M., Yamaguchi S., Konno R., and Hori Y. Spatial learning and long-term potentiation of mutant mice lacking d-amino-acid-oxidase. Neurosci Res 53 (2005) 34-38
117. McOmish C.E., Burrows E.L., Howard M., and Hannan A.J. PLC-beta1 knockout mice as a model of disrupted cortical development and plasticity: behavioral endophenotypes and dysregulation of RGS4 gene expression. Hippocampus 18 (2008) 824-834
118. Mei L., and Xiong W.C. Neuregulin 1 in neural development, synaptic plasticity and schizophrenia. Nat Rev Neurosci 9 (2008) 437-452
119. Mellios N, Huang HS, Baker SP, Galdzicka M, Ginns E, Akbarian S. Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia. Biol Psychiatry [in press].
120. Miyakawa T., Leiter L.M., Gerber D.J., Gainetdinov R.R., Sotnikova T.D., Zeng H., et al. Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci USA 100 (2003) 8987-8992
121. Miyamoto Y., Yamada K., Noda Y., Mishina M., and Nabeshima T. Hyperfunction of dopaminergic and serotonergic neuronal systems in mice lacking the NMDA receptor epsilon1 subunit. J Neurosci 21 (2001) 750-757
122. Mohn A.R., Gainetdinov R.R., Caron M.G., and Koller B.H. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98 (1999) 427-436
123. Morikawa A., Hamase K., Inoue T., Konno R., Niwa A., and Zaitsu K. Determination of free d-aspartic acid, d-serine and d-alanine in the brain of mutant mice lacking d-amino acid oxidase activity. J Chromatogr B Biomed Sci Appl 757 (2001) 119-125
124. Morris D.W., Murphy K., Kenny N., Purcell S.M., McGhee K.A., Schwaiger S., et al. Dysbindin (DTNBP1) and the biogenesis of lysosome-related organelles complex 1 (BLOC-1): main and epistatic gene effects are potential contributors to schizophrenia susceptibility. Biol Psychiatry 63 (2008) 24-31
125. Moy S.S., Perez A., Koller B.H., and Duncan G.E. Amphetamine-induced disruption of prepulse inhibition in mice with reduced NMDA receptor function. Brain Res 1089 (2006) 186-194
126. Muir W.J., Pickard B.S., and Blackwood D.H. Disrupted-in-schizophrenia-1. Curr Psychiatry Rep 10 (2008) 140-147
127. Mukai J., Liu H., Burt R.A., Swor D.E., Lai W.S., Karayiorgou M., et al. Evidence that the gene encoding ZDHHC8 contributes to the risk of schizophrenia. Nat Genet 36 (2004) 725-731
128. Mukai J., Dhilla A., Drew L.J., Stark K.L., Cao L., MacDermott A.B., et al. Palmitoylation-dependent neurodevelopmental deficits in a mouse model of 22q11 microdeletion. Nat Neurosci 11 (2008) 1302-1310
129. Munafò M.R., Bowes L., Clark T.G., and Flint J. Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: a meta-analysis of case-control studies. Mol Psychiatry 10 (2005) 765-770
130. Munafò M.R., Thiselton D.L., Clark T.G., and Flint J. Association of the NRG1 gene and schizophrenia: a meta-analysis. Mol Psychiatry 11 (2006) 539-546
131. Murphy K.C., Jones L.A., and Owen M.J. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 56 (1999) 940-945
132. Murphy K.C., and Owen M.J. Velo-cardio-facial syndrome: a model for understanding the genetics and pathogenesis of schizophrenia. Br J Psychiatry 179 (2001) 397-402
133. Numakawa T., Yagasaki Y., Ishimoto T., Okada T., Suzuki T., Iwata N., et al. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet 13 (2004) 2699-2708
134. 2+/calmodulin-dependent protein kinase II. J Biol Chem 279 (2004) 17980-17988
135. O'Tuathaigh C.M., O'Sullivan G.J., Kinsella A., Harvey R.P., Tighe O., Croke D.T., et al. Sexually dimorphic changes in the exploratory and habituation profiles of heterozygous neuregulin-1 knockout mice. Neuroreport 17 (2006) 79-83
136. O'Tuathaigh C.M.P., Babovic D., O'Meara G., Clifford J.J., Croke D.T., and Waddington J.L. Susceptibility genes for schizophrenia: phenotypic characterisation of mutant models. Neurosci Biobehav Rev 31 (2007) 60-78
137. O'Tuathaigh C.M., Babovic D., O'Sullivan G.J., Clifford J.J., Tighe O., Croke D.T., et al. Phenotypic characterization of spatial cognition and social behavior in mice with 'knockout' of the schizophrenia risk gene neuregulin 1. Neuroscience 147 (2007) 18-27
138. O'Tuathaigh C.M., O'Connor A.M., O'Sullivan G.J., Lai D., Harvey R., Croke D.T., et al. Disruption to social dyadic interactions but not emotional/anxiety-related behaviour in mice with heterozygous 'knockout' of the schizophrenia risk gene neuregulin-1. Prog Neuropsychopharmacol Biol Psychiatry 32 (2008) 462-466
139. Owen M.J., Craddock N., and O'Donovan M.C. Schizophrenia: genes at last?. Trends Genet 21 (2005) 518-525
140. Papaleo F., Crawley J.N., Song J., Lipska B.K., Pickel J., Weinberger D.R., et al. Genetic dissection of the role of catechol-O-methyltransferase in cognition and stress reactivity in mice. J Neurosci 28 (2008) 8709-8723
141. Paterlini M., Zakharenko S.S., Lai W.S., Qin J., Zhang H., Mukai J., et al. Transcriptional and behavioral interaction between 22q11.2 orthologs modulates schizophrenia-related phenotypes in mice. Nat Neurosci 8 (2005) 1586-1594
142. Paylor R., McIlwain K.L., McAninch R., Nellis A., Yuva-Paylor L.A., Baldini A., et al. Mice deleted for the DiGeorge/velocardiofacial syndrome region show abnormal sensorimotor gating and learning and memory impairments. Hum Mol Genet 10 (2001) 2645-2650
143. Paylor R., Glaser B., Mupo A., Ataliotis P., Spencer C., Sobotka A., et al. Tbx1 haploinsufficiency is linked to behavioral disorders in mice and humans: implications for 22q11 deletion syndrome. Proc Natl Acad Sci USA 103 (2006) 7729-7734
144. Perkins D.O., Jeffries C.D., Jarskog L.F., Thomson J.M., Woods K., Newman M.A., et al. microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol 8 (2007) R27
145. Pilowsky L.S., Bressan R.A., Stone J.M., Erlandsson K., Mulligan R.S., Krystal J.H., et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry 11 (2006) 118-119
146. Pletnikov M.V., Ayhan Y., Nikolskaia O., Xu Y., Ovanesov M.V., Huang H., et al. Inducible expression of mutant human DISC1 in mice is associated with brain and behavioural abnormalities reminiscent of schizophrenia. Mol Psychiatry 13 (2008) 173-186
147. Powell C.M., and Miyakawa T. Schizophrenia-relevant behavioral testing in rodent models: a uniquely human disorder?. Biol Psychiatry 59 (2006) 1198-1207
148. Powell K.J., Hori S.E., Leslie R., Andrieux A., Schellinck H., Thorne M., et al. Cognitive impairments in the STOP null mouse model of schizophrenia. Behav Neurosci 121 (2007) 826-835
149. Rimer M., Barrett D.W., Maldonado M.A., Vock V.M., and Gonzalez-Lima F. Neuregulin-1 immunoglobulin-like domain mutant mice: clozapine sensitivity and impaired latent inhibition. Neuroreport 16 (2005) 271-275
150. Roberts C., Winter P., Shilliam C.S., Hughes Z.A., Langmead C., Maycox P.R., et al. Neurochemical changes in LPA1 receptor-deficient mice-a putative model of schizophrenia. Neurochem Res 30 (2005) 371-377
151. Rojas P., Joodmardi E., Hong Y., Perlmann T., and Ogren S.O. Adult mice with reduced Nurr1 expression: an animal model for schizophrenia. Mol Psychiatry 12 (2007) 756-766
152. Roy K., Murtie J.C., El-Khodor B.F., Edgar N., Sardi S.P., Hooks B.M., et al. Loss of erbB signaling in oligodendrocytes alters myelin and dopaminergic function, a potential mechanism for neuropsychiatric disorders. Proc Natl Acad Sci USA 104 (2007) 8131-8136
153. Sakae N., Yamasaki N., Kitaichi K., Fukuda T., Yamada M., Yoshikawa H., et al. Mice lacking the schizophrenia-associated protein FEZ1 manifest hyperactivity and enhanced responsiveness to psychostimulants. Hum Mol Genet 17 (2008) 3191-3203
154. Savonenko A.V., Melnikova T., Laird F.M., Stewart K.A., Price D.L., and Wong P.C. Alteration of BACE1-dependent NRG1/ErbB4 signaling and schizophrenia-like phenotypes in BACE1-null mice. Proc Natl Acad Sci USA 105 (2008) 5585-5590
155. Seamans J.K., and Yang C.R. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol 74 (2004) 1-58
156. Shi J., Gershon E.S., and Liu C. Genetic associations with schizophrenia: meta-analyses of 12 candidate genes. Schizophr Res 104 (2008) 96-107
157. Stark K.L., Xu B., Bagchi A., Lai W.S., Liu H., Hsu R., et al. Altered brain microRNA biogenesis contributes to phenotypic deficits in a 22q11-deletion mouse model. Nat Genet 40 (2008) 751-760
158. Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., et al. Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71 (2002) 877-892
159. Stefansson H., Rujescu D., Cichon S., Pietiläinen O.P., Ingason A., Steinberg S., et al. Large recurrent microdeletions associated with schizophrenia. Nature 455 (2008) 232-236
160. Stephan K.E., Baldeweg T., and Friston K.J. Synaptic plasticity and disconnection in schizophrenia. Biol Psychiatry 59 (2006) 929-939
161. Stone J.M., Morrison P.D., and Pilowsky L.S. Glutamate and dopamine dysregulation in schizophrenia-a synthesis and selective review. J Psychopharmacol 21 (2007) 440-452
162. Straub R.E., Jiang Y., MacLean C.J., Ma Y., Webb B.T., Myakishev M.V., et al. Genetic variation in the 6p22.3 gene DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with schizophrenia. Am J Hum Genet 71 (2002) 337-348
163. Sullivan P.F., Lin D., Tzeng J.Y., van den Oord E., Perkins D., Stroup T.S., et al. Genome-wide association for schizophrenia in the CATIE study: results of stage 1. Mol Psychiatry 13 (2008) 570-584
164. Swerdlow N.R., Weber M., Qu Y., Light G.A., and Braff D.L. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology 199 (2008) 331-388
165. Takao K., Yamasaki N., and Miyakawa T. Impact of brain-behavior phenotyping of genetically engineered mice on research of neuropsychiatric disorders. Neurosci Res 58 (2007) 124-132
166. Talkowski M.E., Seltman H., Bassett A.S., Brzustowicz L.M., Chen X., Chowdari K.V., et al. Evaluation of a susceptibility gene for schizophrenia: genotype based meta-analysis of RGS4 polymorphisms from thirteen independent samples. Biol Psychiatry 60 (2006) 152-162
167. Tandon R., Keshavan M.S., and Nasrallah HA. Schizophrenia, "just the facts" what we know in 2008. Part 1. Overview. Schizophr Res 100 (2008) 4-19
168. Tandon R., Keshavan M.S., and Nasrallah HA. Schizophrenia, "just the facts" what we know in 2008. Part 2. Epidemiology and etiology. Schizophr Res 102 (2008) 1-18
169. Tueting P., Doueiri M.S., Guidotti A., David J.M., and Costa E. Reelin down-regulation in mice and psychosis endophenotypes. Neurosci Biobehav Rev 30 (2006) 1065-1077
170. Tuominen H.J., Tiihonen J., and Wahlbeck K. Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis. Schizophr Res 72 (2005) 225-234
171. Tunbridge E.M., Harrison P.J., and Weinberger D.R. Catechol-O-methyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry 60 (2006) 141-151
172. Van Os J., Rutten J.P., and Poulton R. Gene-environments in schizophrenia: review of epidemiological findings and future directions. Schizophr Bull 34 (2008) 1066-1082
173. Waddington J.L., O'Tuathaigh C., O'Sullivan G., Tomiyama K., Koshikawa N., and Croke D.T. Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface. Psychopharmacology 181 (2005) 611-638
174. Waddington J.L., and Morgan M.G. Pathobiology of schizophrenia. In: Lieberman J.A., and Murray R.M. (Eds). Comprehensive care of schizophrenia (2001), Martin Dunitz, London 28-35
175. Waddington J.L., Corvin A.P., Donohoe G., O'Tuathaigh C.M.P., Mitchell K.J., and Gill M. Functional genomics and schizophrenia: endophenotypes and mutant models. Psychiat Clin N Amer 30 (2007) 365-399
176. Weickert C.S., Rothmond D.A., Hyde T.M., Kleinman J.E., Straub R.E., and Reduced DTNBP1. (dysbindin-1) mRNA in the hippocampal formation of schizophrenia patients. Schizophr Res 98 (2008) 105-110
177. Weickert C.S., Straub R.E., McClintock B.W., Matsumoto M., Hashimoto R., Hyde T.M., et al. Human dysbindin (DTNBP1) gene expression in normal brain and in schizophrenic prefrontal cortex and midbrain. Arch Gen Psychiatry 61 (2004) 544-555
178. Weiner I. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology 169 (2003) 257-297
179. Williams H.J., Owen M.J., and O'Donovan M.C. Is COMT a susceptibility gene for schizophrenia?. Schizophr Bull 33 (2007) 635-641
180. Williams N.M., O'Donovan M.C., and Owen M.J. Chromosome 22 deletion syndrome and schizophrenia. Int Rev Neurobiol 73 (2006) 1-27
181. Xu B., Roos J.L., Levy S., van Rensburg E.J., Gogos J.A., and Karayiorgou M. Strong association of de novo copy number mutations with sporadic schizophrenia. Nat Genet 40 (2008) 880-885
182. Yee B.K., Balic E., Singer P., Schwerdel C., Grampp T., Gabernet L., et al. Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile. J Neurosci 26 (2006) 3169-3181
183. Zeng H., Chattarji S., Barbarosie M., Rondi-Reig L., Philpot B.D., Miyakawa T., et al. Forebrain-specific calcineurin knockout selectively impairs bidirectional synaptic plasticity and working/episodic-like memory. Cell 107 (2001) 617-629
184. Zhang R., and Su B. MicroRNA regulation and the variability of human cortical gene expression. Nucleic Acids Res 36 (2008) 4621-4628